跳转至内容
Merck
CN

HT110216

曙红Y溶液,水性

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

NACRES:
NA.47
UNSPSC Code:
41116124
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


form

solution

Quality Level

shelf life

Expiry date on the label.

IVD

for in vitro diagnostic use

concentration

0.5 % (w/v) in water

application(s)

hematology
histology

storage temp.

room temp

Application

通用细胞质复染。 与苏木精和曙红染色一起使用。

Other Notes

经认证的曙红Y,水中含量为0.5%(w/v)。 未酸化。


Still not finding the right product?

Explore all of our products under 曙红Y溶液,水性


存储类别

10 - Combustible liquids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)

法规信息

监管及禁止进口产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Frederik Denorme et al.
Blood, 127(19), 2337-2345 (2016-03-02)
Rapid vascular recanalization forms the basis for successful treatment of cerebral ischemia. Currently, tissue plasminogen activator (t-PA) is the only approved thrombolytic drug for ischemic stroke. However, t-PA does not always result in efficient thrombus dissolution and subsequent blood vessel
Kenneth C Valkenburg et al.
Oncotarget, 8(46), 80265-80277 (2017-11-09)
Prostate cancer is the most diagnosed non-skin cancer in the US and kills approximately 27,000 men per year in the US. Additional genetic mouse models are needed that recapitulate the heterogeneous nature of human prostate cancer. The Wnt/beta-catenin signaling pathway
Senna Staessens et al.
Haematologica, 105(2), 498-507 (2019-05-03)
Ischemic stroke is caused by a thromboembolic occlusion of cerebral arteries. Treatment is focused on fast and efficient removal of the occluding thrombus, either via intravenous thrombolysis or via endovascular thrombectomy. Recanalization, however, is not always successful and factors contributing



全球贸易项目编号

货号GTIN
HT110216-500ML04061838354761